The CTD² Network sponsored Dialogue on Reverse Engineering and Assessment Methods (DREAM) Challenges powered by Sage Bionetworks; invites the community to develop predictive bioinformatics models. Visit the CTD² Pancancer Chemosensitivity DREAM Challenge registration site for details.
Publications
556 Publications Available
July 19, 2019
Nature Communications
Study identifies acetylation as a regulatory mechanism leading ribonucleotide reductase activity, an enzyme that catalyzes the de novo synthesis of precursors required for DNA synthesis.
July 19, 2019
Journal of Biological Chemistry
Review on the role of G protein-coupled receptors as part of cancer signaling networks promoting tumor growth, dissemination, and immune evasion in precision oncology and development of cancer immunotherapies.
July 08, 2019
Annual Review of Neuroscience
Review on astrocyte diversity in the vertebrate central nervous system and their brain area and disease-specific properties and functions.
July 01, 2019
Nature Genetics
CTD2 scientists at Stanford University developed SCIMET, an analytical framework that provides quantitative measurement of dynamics of metastasis in a patient-specific manner; indicates early dissemination of colorectal cancer in the majority of the patients.
July 01, 2019
EBioMedicine
CTD2 scientists at Stanford University showed that radiomic analysis of computed tomography could be used to identify molecular subtypes of head and neck squamous cell carcinomas.
June 10, 2019
Cancer Cell
CTD2 scientists at OHSU demonstrated that sequential therapy with PARP and either WEE1 or ATR inhibitors is effective and potentially less toxic in multiple relevant cancer models.
June 03, 2019
Nature Communications
Integrative genomic analyses of expression profiling, CRISPR-Cas9 and ORF/cDNA, identifies cell-essential genes suppressed by BET-bromodomain inhibition. The study suggests the use of cell-cycle inhibitors in combination with BET-bromodomain inhibitors to treat MYC-amplified medulloblastoma.
June 01, 2019
Gut
Columbia CTD2 researchers developed ADVOCATE, a computational model to analyze gene expression data of epithelial and stromal pancreatic ductal adenocarcinoma samples. These studies indicated a novel classification signature which could facilitate the development of precision oncology approaches.
June 01, 2019
Nature Structural & Molecular Biology
May 16, 2019
Nature Communications
Scientists at the UCSD CTD2 Center showed that epigenetic dysregulation and silencing are associated with chromatin repression and aberrant hypermethylation at the transcription start site in HPV-related oral cancers; independent of CpG island and is associated with MYC pathway activation.
Pages
.